*Sponsored by Bullzeye Media


Hey Folks, Jeff Bishop here.

The markets have been unusually boring this week — trading mostly sideways — and there really hasn’t been any huge news that could shake things up. 

Boring except for my recent Bullseye ideas, that is!!!

You know I can’t ever get enough of fast-moving trade ideas, and right now, I have my eye on a small-cap company that spiked over 20% yesterday – and I think it could just be getting started.

I’ve been killing it on these ideas lately, and if you haven’t been paying attention, you missed my small-cap “Bright Idea 💡” two weeks ago that climbed nearly 50%

the very same day I recommended it…

And you also missed last week’s idea, which jumped 21% day of, and another 20%

premarket the following day.

I don’t mention all of that to “toot my own horn 📯” (well, maybe a little!); I do it to point out that we are in a very hot market.

We don’t get many times like we are seeing right now, so it is especially important to pay attention when the right ideas come along.

Today is one of those times.

Right now, I strongly suggest you pull up this stock chart:

Mangoceuticals, Inc. (Nasdaq: MGRX)

It’s an up-and-coming men’s health and wellness company that’s stock price has been sliding gradually since its IPO in March, but is showing every sign of having finally found its footing.

Based on what I’m seeing, yesterday’s jump could well be just the early innings of a major rally to come.

This is just a beautiful chart.

Currently up around 45% over the last month, all of the dips have been bought, and we have seen a steady accumulation driving it higher.

I would keep an extremely close eye on this one as long as the “GO” trend stays in place.  

Here are three more reasons this stock deserves your attention right now.

Aggressive and growth-oriented marketing

I first heard of MGRX on BarStool Sports’ popular “Only Stans” podcast a few months ago. The company sponsored 8 episodes of the podcast, which reaches an average of 320,000 listeners per episode.

The company’s flagship product is a prescription medication for male “ED” issues called Mango 🥭, which uses the same active ingredients as the other two major drugs in the space.  

You know what they are (the little “blue pill,” and the annoying commercials with couples holding hands in the bathtubs), but I won’t mention them here otherwise this email would go to your spam box!

But unlike those huge multi-billion dollar brands, whose marketing seems to target the elderly, Mango’s marketing seems to target younger, more sexually active audiences. Just a glance at the company’s website will show you what I mean.

In addition to the Barstool Sports show, the company has sponsored podcasts such as:

That’s quite the lineup!

The company has also retained a marketing agency to help with social media advertising on Meta (Instagram/Facebook), Google, and YouTube.

You can check out the company’s YouTube channel here for a sense of their… provocative advertising. As you can see, several of the videos have gone viral and they are pretty darn funny.

In addition — and this is something I think is especially promising — the company in October launched an affiliate marketing program whereby publishers and influencers can sign up at this website to access company-approved media, tools, and content to use on their own marketing platforms.

If all goes well, MGRX expects this program may drive “up to 20% of the Company’s overall gross revenues.”

That’s a huge number!

It’s worth noting for our purposes that while the primary purpose of this comprehensive marketing plan is undoubtedly to increase revenue, it will also increase brand — and, ultimately, stock recognition.

I’m sure I’m not the only one who has come across an ad for an interesting and innovative company and checked out its ticker.

And remember: A little brand recognition goes a long way with these upstart companies. You aren’t likely to read about MGRX on the Wall Street Journal front page, so coming across an ad on a podcast can be the best way potential investors learn about the stock.

Unique appeal

The marketing approach MGRX takes isn’t just arbitrary or cosmetic: The company has a special appeal to younger people…

A 2013 study found that ED affected 26% of men younger than 40, almost half of whom had severe ED. Obviously, there’s a social stigma associated with ED, and many men who have it find it embarrassing. That’s probably especially true for young men.

MGRX has a solution to at least help mitigate that concern: telemedicine

The company makes it simple to book an online telehealth visit, then medical providers in its medical network review and approve a prescription if medically appropriate. 

At that point, the product then gets sent directly to the consumer — no awkward in-person doctor visit or pharmacy visit is necessary.

Frankly, I had heard about telemedicine during Covid, but I never realized it could be that simple to book an online appointment and receive a prescription in the mail, all thanks to the same company.

That kind of private, low-drag approach to ED treatment has got to be successful, and sure enough the company has been killing it on revenue: It’s up 28.8% from Q1 to Q2, 42.5% from Q2 to Q3, and 59% from Q1 to Q3. 

As an investor, that’s the kind of growth you love to see in this market.

Product diversification

On November 16, MGRX announced an expansion of its product line beyond Mango: a new hair-growth treatment it has dubbed “Grow.” 

According to the company’s press release, “The custom compounded hair growth treatment combines four clinically proven hair growth products encapsulated in convenient chewable, mint-flavored tablets.”

It appears to be that announcement that has led the stock price to nearly double in the span of three weeks — and for good reason.

Clearly, men concerned about ED may also be concerned about hair loss, and MGRX has long stated its intention to expand into that market, as well as “weight loss, performance, and various hormone therapies.”

If all of these problems can be diagnosed and treated with the same approach MGRX has taken with ED, I’d expect a great deal of appeal. 

And indeed, MGRX has taken steps to make just that possible. Last week, the company announced its selection of a company to offer its customers “a minimally invasive FDA approved at-home blood collection device and testing service,” TRYBE Labs.

According to the company, the blood tests can achieve a “full range of testing, and physician-read results for male health and performance evaluation — including hormone, thyroid and vitamin levels.”

Again, I didn’t realize this type of at-home service was possible, and it will enable MGRX to diversify into all the areas mentioned above. The appeal is obvious.


I have to be honest: I haven’t come across a small company this intriguing in a long time…

Between its dynamic, multi-pronged approach to marketing… its innovative use of telemedicine… and its now-expanding product line, I won’t be surprised if those revenue numbers keep accelerating.

Over the last three weeks, investors seem to have finally caught on, and as I mentioned, the current stock price, $.83, is nearly double the November low it hit on the day it announced “Grow.”

Is this a ceiling, or will MGRX have the… ahem… stamina to keep climbing? The go/no-go algo is signaling “go,” and I have to agree.

At the very least, I think this stock deserves your sincere attention. My conclusions are my own, and you’ll have to make up your own mind, and of course, always have a trading game plan that makes sense for you.

As always, check out the stock’s chart, but with this company, I especially recommend checking out their main website, their affiliate website, and their social media.

To Your Success,

Jeff Bishop


*This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.




*PAID ADVERTISEMENT. Raging Bull has currently been paid twelve thousand dollars from Bullzeye Media who was compensated by a third party not affiliated with the Company for advertising Mangoceuticals, Inc. from a period beginning on December 6 through December 7, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Mangoceuticals, Inc., increased trading volume, and possibly an increased share price of Mangoceuticals, Inc.’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in Mangoceuticals, Inc., though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication.

FOR COMMERCIAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for commercial and informational purposes only. A portion of our business is engaged in the promotion, marketing, and advertising of companies including public companies. A portion of Raging Bull’s business model is to receive financial compensation to promote public companies, conduct investor relations advertising and marketing, and publicly disseminate information regarding public companies through our websites email, SMS, and push notifications among other methods of communication. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. All material information contained in this advertisement is based on information generally available to the public, including information released to the public or filed by the Company with applicable regulators which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Never invest in any stock featured in this advertisement, on our site or emails unless you can afford to lose your entire investment.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

USE OF FORWARD-LOOKING STATEMENTS. Our advertisements including this advertisement and related emails, reports and alerts may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information in this advertisement, related emails, reports or alerts or on our website or media webpage. This information is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec .gov/edgar/searchedgar/company search

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.

WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.